PUT/VERTEX PHARMACEUTICALS/300/0.1/17.01.25 | Real-time BOERSE MUENCHEN 12:26:10 2024-07-11 pm EDT | ||
| 0.148 EUR | +12.98% |
|
| Current month | -18.63% | ||
| 1 month | -17.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 0.148 | +12.98% |
| 24-07-10 | 0.131 | +16.96% |
| 24-07-09 | 0.112 | -4.27% |
| 24-07-08 | 0.117 | -29.52% |
| 24-07-05 | 0.166 | -1.19% |
Real-time BOERSE MUENCHEN
Last update July 11, 2024 at 12:26 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GZ7P47 |
| ISIN | DE000GZ7P478 |
| Date issued | 2023-01-25 |
| Strike | 300 $ |
| Maturity | 2025-01-17 (190 Days) |
| Parity | 10 : 1 |
| Emission price | 3.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.75 € |
|---|---|
| Lowest since issue | 0.096 € |
| Spread | 0.3 € |
| Spread % | 69.77% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
491.6
USD
Average target price
473.1
USD
Spread / Average Target
-3.77%
- Stock Market
- Warrants
- Warrant
